Answers are grounded in this paper and cite their sources.
This simple, universally applicable staging system stratifies patients with both ATTRwt and ATTRv amyloid cardiomyopathy into prognostic categories. It will be of value in the design of forthcoming clinical trials of novel amyloid-specific therapies.
No takes yet. Share an insight, caveat, or question.
Gillmore et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: